Monkey treatment may be solution to coronavirus

Results support testing antiviral against 2019 novel coronavirus.

The experimental antiviral remdesivir successfully prevented disease in rhesus macaques infected with Middle East respiratory syndrome coronavirus (MERS-CoV), according to a new study from National Institutes of Health scientists. Remdesivir prevented disease when administered before infection and improved the condition of macaques when given after the animals already were infected.

The new report from NIH’s National Institute of Allergy and Infectious Diseases (NIAID) appears in the Proceedings of the National Academy of Sciences. MERS-CoV is closely related to the 2019 novel coronavirus (2019-nCoV) that has grown to be a global public health emergency since cases were first detected in Wuhan, China, in December.

Remdesivir has previously protected animals against a variety of viruses in lab experiments. The drug has been shown experimentally to effectively treat monkeys infected with Ebola and Nipah viruses. Remdesivir also has been investigated as a treatment for Ebola virus disease in people.

The current study was conducted at NIAID’s Rocky Mountain Laboratories in Hamilton, Montana. The work involved three groups of animals: those treated with remdesivir 24 hours before infection with MERS-CoV; those treated 12 hours after infection (close to the peak time for MERS-CoV replication in these animals); and untreated control animals.

The scientists observed the animals for six days. All control animals showed signs of respiratory disease. Animals treated before infection fared well: no signs of respiratory disease, significantly lower levels of virus replication in the lungs compared to control animals, and no lung damage. Animals treated after infection fared significantly better than the control animals: disease was less severe than in control animals, their lungs had lower levels of virus than the control animals, and the damage to the lungs was less severe.

The scientists indicate that the promising study results support additional clinical trials of remdesivir for MERS-CoV and 2019-nCoV. At least two clinical trials of remdesivir for 2019-nCoV are under way in China, and other patients with 2019-nCoV infection have received the drug under a compassionate use protocol.

The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, also provided support for this study. Gilead Sciences, Inc., developed remdesivir, also known as GS-5734, and collaborated in the research.

MERS-CoV emerged in Saudi Arabia in 2012. Through December 2019, the World Health Organization had confirmed 2,499 MERS-CoV cases and 861 deaths (or about 1 in 3). Because about one-third of MERS-CoV cases spread from infected people being treated in healthcare settings, the scientists suggest that remdesivir could effectively prevent disease in other patients, contacts of patients, and healthcare workers. They also note the drug might help patients who are diagnosed with MERS or 2019-nCoV if given soon after symptoms start.

 

The Liberum

The subtitle of The Liberum ("the voice of the people is the voice of God") reflects the concept that the collective opinions and will of the people carry divine importance. They embody truth and wisdom, particularly in a non-partisan marketplace that profiles itself as a marketplace of free ideas and thoughts.
See full bio >
The Liberum runs on your donation. Fight with us for a free society.
Donation Form (#6)

More articles you might like

Islamo-leftism is the most important new ideology of our time

The radical left-wing Dutch politician and leader of the GreenLeft and Labour, former European Commissioner, […]

China’s gains won’t topple the West - yet

China’s rise as a global power is no longer a distant prospect – it is […]

The Art of Ghosting: Have we all become disappearing acts?

From Beirut to Dubai to the West, silence has become the new language of rejection […]
- by Rafael Baroch on 01/09/2025

ESSAY: Notes from inside the Pyramid of Care

We were promised care. Not love, not freedom, not even happiness – just care—a modest […]

The rise of the Jihadist terrorist threats in the West

The threat of Jihadist terrorists in Europe against dissidents is on the rise. The Islamic […]
- by Ahsan Ali on 28/08/2025

India and Pakistan's South Asian - Middle Eastern Political Crisis

The connection between the Middle East and South Asia is predictable and understandable, given their […]